Compare Natera Inc. Common Stock (NTRA) vs Welltower Inc. Common Stock (WELL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Welltower Inc. Common Stock — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Welltower Inc. Common Stock trades at $235.46 (market cap $165.83B). The key difference: Welltower Inc. Common Stock is far larger — about 2.9× Natera Inc. Common Stock's market cap, and Welltower Inc. Common Stock pays a 1.48% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Welltower Inc. Common Stock for 6 Days on average.
| NTRA | WELL | |
|---|---|---|
Market Cap | $57.03B | $165.83B |
Volume | 1,131,157 | 2,216,134 |
Sector | Health | Real Estate |
52-Week High | $425.64 | $252.07 |
52-Week Low | $179.42 | $172.08 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $56.18B | $183.59B |
Dividend Yield | — | 1.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
WELL trades at $230.14, down 0.07% on the day, with a bullish technical signal supported by moving averages and a strong ADX trend indicator. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating in Q1 2026. Revenue grew to $10.67B in 2025, with net income of $936.85M, and is projected to rise to $12.6B in 2026. Analyst sentiment is strongly positive, with 71.43% buy ratings and a consensus price target of $257.08, indicating potential upside. Recent news highlights strategic acquisitions and positive coverage on senior housing demand trends.
Outlook: WELL benefits from strong demographic tailwinds in senior housing and robust analyst support, but high valuation multiples and earnings volatility pose risks. The stock's current price near support at $226 suggests a cautious entry point, with upside driven by execution on growth projections and sector tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Welltower Inc. Common Stock
Welltower is a real estate investment trust focused on healthcare properties. Its portfolio includes senior housing, outpatient medical facilities, and other health-related real estate.
Read more on WELL →
